Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MQ710 Alone and in Combination With Pembrolizumab in Solid Tumors
NCT05859074Phase 1Recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- May 2023
- Primary completion
- May 2028
- Modality
- Gene Editing, Gene Silencing, Oncolytic Viruses
- Countries
- 1
01
Overview
Phase 1, open-label trial of MQ710 in solid tumor (2 arms), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Adverse Events and Serious Adverse Events at 2 years. Started May 2023; status: recruiting.
02
Drugs
MQ710
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05859074.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05859074.